Literature DB >> 8702571

The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1.

A Rana1, K Gallo, P Godowski, S Hirai, S Ohno, L Zon, J M Kyriakis, J Avruch.   

Abstract

SPRK (also called PTK-1 and MLK-3), a member of the mixed lineage kinase subfamily of (Ser/Thr) protein kinases, encodes an amino-terminal SH3 domain followed by a kinase catalytic domain, two leucine zippers interrupted by a short spacer, a Rac/Cdc42 binding domain, and a long carboxyl-terminal proline-rich region. We report herein that SPRK activates the stress-activated protein kinases (SAPKs) but not ERK-1 during transient expression in COS cells; the p38 kinase is activated modestly (1.3-2 fold) but consistently. SPRK also activates cotransfected SEK-1/MKK-4, a dual specificity kinase which phosphorylates and activates SAPK. Reciprocally, expression of mutant, inactive SEK-1 inhibits completely the basal and SPRK-activated SAPK activity. Immunoprecipitated recombinant SPRK is able to phosphorylate and activate recombinant SEK-1 in vitro to an extent comparable to that achieved by MEK kinase-1. These results identify SPRK as a candidate upstream activator of the stress-activated protein kinases, acting through the phosphorylation and activation of SEK-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702571     DOI: 10.1074/jbc.271.32.19025

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  A new identity for MLK3 as an NIMA-related, cell cycle-regulated kinase that is localized near centrosomes and influences microtubule organization.

Authors:  Katherine I Swenson; Katharine E Winkler; Anthony R Means
Journal:  Mol Biol Cell       Date:  2003-01       Impact factor: 4.138

2.  Regulation of apoptotic c-Jun N-terminal kinase signaling by a stabilization-based feed-forward loop.

Authors:  Zhiheng Xu; Nikolay V Kukekov; Lloyd A Greene
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

Review 3.  MAP kinase pathways: the first twenty years.

Authors:  Joseph Avruch
Journal:  Biochim Biophys Acta       Date:  2006-11-15

4.  Resveratrol prevents impairment in activation of retinoic acid receptors and MAP kinases in the embryos of a rodent model of diabetic embryopathy.

Authors:  Chandra K Singh; Ambrish Kumar; Holly A LaVoie; Donald J DiPette; Ugra S Singh
Journal:  Reprod Sci       Date:  2012-04-24       Impact factor: 3.060

5.  Evidence for a role of mixed lineage kinases in neuronal apoptosis.

Authors:  M Mota; M Reeder; J Chernoff; C E Bazenet
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

Review 6.  Network Motifs in JNK Signaling.

Authors:  Vasudha Sehgal; Prahlad T Ram
Journal:  Genes Cancer       Date:  2013-09

7.  Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3.

Authors:  Rajakishore Mishra; Manoj K Barthwal; Gautam Sondarva; Basabi Rana; Lucas Wong; Malay Chatterjee; James R Woodgett; Ajay Rana
Journal:  J Biol Chem       Date:  2007-08-21       Impact factor: 5.157

Review 8.  Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson's disease.

Authors:  Anumantha Kanthasamy; Huajun Jin; Suneet Mehrotra; Rajakishore Mishra; Arthi Kanthasamy; Ajay Rana
Journal:  Neurotoxicology       Date:  2009-12-11       Impact factor: 4.294

9.  PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia.

Authors:  A Abo; J Qu; M S Cammarano; C Dan; A Fritsch; V Baud; B Belisle; A Minden
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

10.  MLK3 limits activated Galphaq signaling to Rho by binding to p63RhoGEF.

Authors:  Katherine I Swenson-Fields; Joshua C Sandquist; Jessica Rossol-Allison; Irene C Blat; Krister Wennerberg; Keith Burridge; Anthony R Means
Journal:  Mol Cell       Date:  2008-10-10       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.